Drugs / Flutemetamol

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05374564 Aug 2022 → Nov 2024 cardiomyopathy Yale University Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00785759 Sep 2008 → Mar 2009 Alzheimer disease, amnestic disorder GE Healthcare Completed No outcome recorded
Phase 37 trials
Phase 3 NCT02353949 May 2015 → Dec 2019 Alzheimer disease, cognitive impairment with or without cerebellar ataxia University of Zurich Terminated No outcome recorded
Phase 3 NCT02164643 Jun 2014 → Oct 2019 Alzheimer disease University Hospital, Bordeaux Completed No outcome recorded
Phase 3 NCT01265394 Dec 2010 → Mar 2011 GE Healthcare Completed No outcome recorded
Phase 3 NCT01165554 May 2010 → Nov 2011 GE Healthcare Completed No outcome recorded
Phase 3 NCT01092546 Mar 2010 → Apr 2011 normal pressure hydrocephalus GE Healthcare Terminated No outcome recorded
Phase 3 NCT01053312 Dec 2009 → Jul 2010 normal pressure hydrocephalus GE Healthcare Completed No outcome recorded
Phase 3 NCT01028053 Dec 2009 → Jan 2014 Alzheimer disease, cognitive impairment with or without cerebellar ataxia GE Healthcare Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Flutemetamol ClinicalTrials.gov intervention name — accepted as the source's own label NCT01165554
7

NCT02353949

NCT01053312

NCT01028053

NCT05374564

NCT01092546

NCT01265394

NCT02164643

Known as [18F]flutemetamol “Drug: [18F] Flutemetamol” NCT01165554
Known as AH110690 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00785759
Known as Flutemetamol (18F) Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.” NCT01165554
1

Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.” NCT01265394

Known as flutemetamol F 18 “Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.” PMID 27955679 Dec 2016
Known as Vizamyl “PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose” NCT02353949
Modality Diagnostic / imaging agent “Flutemetamol (18F) Injection PET tracer” NCT01028053
Route Intravenous “I.V. dose” NCT00785759